Neoadjuvant and Adjuvant Chemotherapy for Pancreatic Adenocarcinoma: Literature Review and Our Experience of NAC-GS

Neoadjuvant and Adjuvant Chemotherapy for Pancreatic Adenocarcinoma: Literature Review and Our Experience of NAC-GS

In addition to established evidence of the efficacy of adjuvant chemotherapy (AC) for pancreatic ductal adenocarcinoma (PDAC), evidence of the effects of neoadjuvant treatments (NATs), including chemotherapy and chemoradiotherapy, has also been accumulating. Recent results from prospective studies a...

Full description

Bibliographic Details
Main Authors:	Taku Aoki, Shozo Mori, Keiichi Kubota
Format:	Article
Language:	English
Published:	MDPI AG 2024-02-01
Series:	Cancers
Subjects:	pancreatic ductal adenocarcinoma neoadjuvant adjuvant gemcitabine S-1
Online Access:	https://www.mdpi.com/2072-6694/16/5/910

Similar Items

Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data
by: Francesco Giovinazzo, et al.
Published: (2020-08-01)

Clinical Outcomes of Neoadjuvant Versus Adjuvant Chemotherapy on Muscle-invasive Bladder Cancer
by: DENG Kangli, et al.
Published: (2019-04-01)

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
by: Victor Mortier, et al.
Published: (2022-12-01)

First case report of neoadjuvant gemcitabine and S-1 for locally advanced unresectable duodenal adenocarcinoma
by: Jiro Kimura, et al.
Published: (2022-05-01)

Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma
by: Bo Li, et al.
Published: (2021-05-01)

Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer?
by: Elisabetta Fenocchio, et al.
Published: (2019-10-01)

Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy
by: Sumit Sahni, et al.
Published: (2023-09-01)

Risk stratification of stage II rectal mucinous adenocarcinoma to predict the benefit of adjuvant chemotherapy following neoadjuvant chemoradiation and surgery
by: Yahang Liang, et al.
Published: (2024-03-01)

Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going
by: Alessandro Coppola, et al.
Published: (2023-05-01)

Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma?
by: Hyung Sun Kim, et al.
Published: (2021-02-01)

Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015)
by: Daisaku Yamada, et al.
Published: (2021-08-01)

The synergism of Clinacanthus nutans Lindau extracts with gemcitabine: downregulation of anti-apoptotic markers in squamous pancreatic ductal adenocarcinoma
by: Ling-Wei Hii, et al.
Published: (2019-09-01)

Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasing Perioperative Complications
by: Christopher Ryan Deig, et al.
Published: (2022-01-01)

Neoadjuvant Chemotherapy and Adjuvant Chemoradiation Therapy in the Treatment of Resected Gastric Adenocarcinoma: A Case Series
by: Christina Hadzitheodorou, et al.
Published: (2017-04-01)

Neoadjuvant chemotherapy improves outcomes in resectable pancreatic adenocarcinoma
by: Wade Christopher, et al.
Published: (2022-12-01)

Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis
by: Bathiya Ratnayake, et al.
Published: (2020-07-01)

The role of neoadjuvant chemotherapy in patients with primary resectable pancreatic cancer: A retrospective cohort study
by: Igor E. Khatkov, et al.
Published: (2023-08-01)

The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis
by: Saber Amin, et al.
Published: (2020-06-01)

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?
by: Chenqi Wang, et al.
Published: (2022-06-01)

Clinical Outcomes of Conversion Surgery after FOLFIRINOX in Patients with Unresectable Advanced Pancreatic Cancer: A Retrospective Cohort Study at a Single Center
by: Naoki Mita, et al.
Published: (2021-06-01)

Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift
by: Akhil Chawla, et al.
Published: (2019-10-01)

Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome?
by: Shelize Khakoo, et al.
Published: (2021-08-01)

Feasibility of laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer: a retrospective cohort study
by: Zheng Li, et al.
Published: (2024-01-01)

Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?
by: Nabil Ismaili, et al.
Published: (2011-09-01)

Survival benefit after neoadjuvant or adjuvant radiotherapy for stage II–III gastroesophageal junction adenocarcinoma: A large population-based cohort study
by: Zhichao Zuo, et al.
Published: (2022-10-01)

A case of complete resection of prostate stromal sarcoma after neoadjuvant chemotherapy
by: Naoto Hodotsuka, et al.
Published: (2023-07-01)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
by: Zong Y, et al.
Published: (2020-12-01)

A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma
by: Ma Yue, et al.
Published: (2011-03-01)

Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma
by: Luise Rupp, et al.
Published: (2024-04-01)

SMAD4 Positive Pancreatic Ductal Adenocarcinomas Are Associated with Better Outcomes in Patients Receiving FOLFIRINOX-Based Neoadjuvant Therapy
by: Marie-Lucie Racu, et al.
Published: (2023-07-01)

Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma
by: Kaidong Liu, et al.
Published: (2022-08-01)

Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion
by: Ahmed Eldefrawy, et al.
Published: (2012-01-01)

Feasibility study of adjuvant chemotherapy with S-1 after curative esophagectomy following neoadjuvant chemotherapy for esophageal cancer
by: Noriyuki Hirahara, et al.
Published: (2022-06-01)

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group
by: Thomas J. Ettrich, et al.
Published: (2018-12-01)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
by: Feng Shao, et al.
Published: (2018-06-01)

Comparison of responses to neoadjuvant and adjuvant chemotherapies in muscle-invasive bladder cancer
by: Serhat Sekmek, et al.
Published: (2023-11-01)

Pancreatic Cancer Chemoresistance to Gemcitabine
by: Manoj Amrutkar, et al.
Published: (2017-11-01)

A comparison of neoadjuvant chemotherapy with gemcitabine versus docetaxel plus cisplatin in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis
by: Liu T, et al.
Published: (2018-11-01)

Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate‐adjusted analysis at the pre‐adjuvant chemotherapy timing
by: Ningzhen Fu, et al.
Published: (2022-09-01)

Neoadjuvant Chemoradiotherapy versus Chemotherapy for Gastroesophageal Junction Adenocarcinoma; Which Is the Optimal Treatment Option?
by: Eric Zandirad, et al.
Published: (2022-11-01)